Myeloid cells are pivotal within the immunosuppressive tumour microenvironment. The
accumulation of tumour-modified myeloid cells derived from monocytes or neutrophils …

The success of atezolizumab plus bevacizumab treatment contributed to a shift in systemic
therapies for hepatocellular carcinoma (HCC) towards combinations that include cancer …

Immune checkpoint inhibitor (ICI) therapy targeting anti-programmed cell death-1 (anti-PD-
1) or its ligand (anti-PD-L1) is the backbone of numerous combination regimens aimed at …

Suppression of antitumor immune responses is one of the main mechanisms by which tumor
cells escape from destruction by the immune system. Myeloid-derived suppressor cells …

Cancer immunotherapy (CIT) with antibodies targeting the programmed cell death 1 protein
(PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis have changed the standard of care in …

Immune associated cells in the microenvironment have a significant impact on the
development and progression of hepatocellular carcinoma (HCC) and have received more …

Background Regorafenib and other multikinase inhibitors may enhance antitumor efficacy of
anti-program cell death-1 (anti-PD1) therapy in hepatocellular carcinoma (HCC). Its …

Abstract Purpose: Transcription factor C/EBP-α (CCAAT/enhancer-binding protein alpha)
acts as a master regulator of hepatic and myeloid functions and multiple oncogenic …

Myeloid-derived suppressor cells (MDSCs) are major negative regulators of immune
responses in cancer and chronic infections. It remains unclear if regulation of MDSC activity …

Vascular endothelial growth factor-A (VEGF) is the predominant angiogenic factor that is
expressed in solid tumors. Besides its critical function in mediating tumor angiogenesis …